At a Glance:
- Guandata has raised $44.2 million in the latest funding by the US investment firm Tiger Global Management.
- The funds will be used to deepen the firm’s products matrix, upgrade client systems and construct key ecosystems.
- Tiger Global expects data analysis tools and business intelligence solutions to jump 100 times in the next decade.
Guandata—the Chinese business intelligence solutions provider has raised $44.2 million in the latest funding round which was led by the US investment firm Tiger Global Management.
The other participants in the series funding included Sequoia Capital China, Linear Capital, Xiang He Capital, and Unicorn Capital Partners.
The CEO and Founder, Su Chunyuan commented, “The proceeds from the Series C round will be used to deepen the firm’s products matrix, upgrade client systems and construct key ecosystems.”
Expecting demand for data analysis tools
Su also stated in media reports that the firm, which counts British consumer goods firm Unilever, Chinese health drink brank Genki Forest and lifestyle platform Xiaohongshu among its clients, is expecting demand for its data analysis tools and business intelligence solutions to jump by as much as 100 times over the next decade.
In the coming years, Chinese companies will demand high-quality local services as the development of AI technologies lowers the user threshold of data analysis.
Last year, Guandata locked around $15 million in Series B+ round in March that was led by the Hong Kong-based Unicorn Capital.
Guandata, HQ in Hangzhou, with offices in locations in Beijing, Shanghai, Shenzhen, and other places. The company is striving to make decision-making more intelligent by providing customers with AI+BI next-gen intelligent data analysis platform and mature data analysis practices applied in the retail industry. With intelligent decision-making as the goal, it has been constructed step by step and continually upgraded to create a future-oriented intelligent decision-making brain for customers.
Also Read: Data in the time of Covid